VELCADE ® (bortezomib) for Injection
VELCADE is a proteasome inhibitor indicated for:
• treatment of patients with multiple myeloma
• treatment of patients with mantle cell lymphoma
DOSAGE FORMS AND STRENGTHS
• Single-use vial contains 3.5 mg of bortezomib as lyophilized powder
Get In Touch
Get in touch with us at South Delhi Pharma (SDM), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Bortezomib is an anti-cancer drug and the first therapeutic proteasome inhibitor to be used in humans. Proteasomes are cellular complexes that break down proteins. In some cancers, the proteins that normally kill cancer cells are broken down too quickly. Bortezomib interrupts this process and lets those proteins kill the cancer cells. It is approved in the U.S. and Europe for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.